Hybrid eventIn-person & virtual
June 24–26, 2027Rome, Italy

Talk Details · Neurology 2027

Anticipating a precision medicine model for neurodegenerative diseases: Opportunities and strategies

Keynote · In-Person · Day 1

Abstract

About this talk

Unprecedented advances in Alzheimer’s disease biomarker science have transformed the landscape of early detection, diagnosis, and treatment, ushering in the first new disease-modifying therapies in more than two decades. Innovations in neuroimaging, blood-based biomarkers, and precision medicine offer extraordinary opportunities to identify Alzheimer’s disease earlier, improve diagnostic accuracy, and expand access to emerging treatments. In particular, blood-based biomarkers have the potential to revolutionize clinical care by providing scalable, accessible, and cost-effective tools that can reach populations historically underserved by traditional diagnostic approaches.

Despite these remarkable advances, significant challenges remain. Much of the research supporting current biomarker technologies, diagnostic frameworks, and therapeutic interventions has been conducted in populations lacking sufficient racial, ethnic, socioeconomic, and geographic diversity. Consequently, the generalizability, clinical performance, and equitable implementation of these innovations across diverse communities remain uncertain. Without deliberate efforts to address these gaps, scientific breakthroughs risk perpetuating or even widening existing disparities in Alzheimer’s disease diagnosis, treatment, and outcomes.

The Health & Aging Brain Study – Health Disparities (HABS-HD) represents the most comprehensive investigation of Alzheimer’s disease biomarkers across diverse communities conducted to date. Through its innovative, multidisciplinary approach, HABS-HD is generating critical insights into the complex relationships among biological, environmental, social, and health-related factors that influence brain aging and Alzheimer’s disease risk. These findings are helping redefine how biomarkers are evaluated, interpreted, and implemented across populations while establishing a foundation for more inclusive approaches to precision medicine.

In this presentation, Dr. Sid O’Bryant, an internationally recognized leader in Alzheimer’s disease research, brain aging, and health disparities, will highlight groundbreaking discoveries emerging from HABS-HD and discuss their implications for the future of Alzheimer’s disease research and clinical care. Particular emphasis will be placed on the opportunities and challenges associated with implementing blood-based biomarkers, advancing equitable access to disease-modifying therapies, and developing population-informed approaches to risk assessment, early detection, and intervention.

Dr. O’Bryant will also identify critical scientific, clinical, and policy priorities necessary to translate these advances into meaningful improvements in brain health across communities worldwide. By integrating cutting-edge biomarker science with a commitment to inclusivity, accessibility, and individualized care, this presentation will outline a transformative pathway toward precision brain health. The overarching vision is to move beyond a one-size-fits-all approach to Alzheimer’s disease and establish a future in which scientific innovation benefits everyone, advancing the ambitious goal of A World of Optimal Brain Health for All.

Speaker

About the speaker

Sid O Bryant

Sid O Bryant

University of North Texas Health Fort Worth, United States

View full speaker profile →

Join the Neurology 2027 delegation

Rome · June 24–26, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.

Chat with us